Your session is about to expire
← Back to Search
Other
Genomically Directed Monotherapy for Breast Cancer
Phase 2
Waitlist Available
Research Sponsored by Bryan Schneider, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from c1d1 until death or up to a maximum of 60 months
Awards & highlights
Study Summary
This trial will test if personalized therapy for each individual's tumor will be more effective than the current standard of care.
Eligible Conditions
- Breast Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from c1d1 until death or up to a maximum of 60 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from c1d1 until death or up to a maximum of 60 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Percentage of Participants With Two-Year Disease-Free Survival (DFS)
Secondary outcome measures
Comparison Between One Year Disease Free Survival
Comparison Between Overall Disease-Free Survival
Five-Year Overall Survival (OS) Rate
+1 moreSide effects data
From 2022 Phase 2 trial • 193 Patients • NCT0210138551%
FATIGUE
32%
NAUSEA
28%
DIARRHEA
21%
CONSTIPATION
18%
BACK PAIN
17%
HEADACHE
14%
DYSPNEA
13%
ANOREXIA
13%
HYPERTENSION
13%
COUGH
13%
PERIPHERAL SENSORY NEUROPATHY
13%
NEUTROPHIL COUNT DECREASED
11%
ARTHRALGIA
10%
VOMITING
8%
ANEMIA
8%
RASH ACNEIFORM
8%
ALKALINE PHOSPHATASE INCREASED
8%
PLATELET COUNT DECREASED
7%
DYSPEPSIA
7%
MUCOSITIS ORAL
7%
MYALGIA
6%
DYSGEUSIA
6%
PRURITUS
6%
HOT FLASHES
6%
HYPOTHYROIDISM
6%
INSOMNIA
6%
ASPARTATE AMINOTRANSFERASE INCREASED
6%
PAIN
6%
PAIN IN EXTREMITY
6%
HYPERGLYCEMIA
4%
ABDOMINAL PAIN
4%
DIZZINESS
4%
BLURRED VISION
4%
LYMPHOCYTE COUNT DECREASED
4%
CHEST WALL PAIN
4%
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDER
4%
WHITE BLOOD CELL DECREASED
4%
ANXIETY
4%
NASAL CONGESTION
4%
URINARY TRACT INFECTION
4%
PALMAR-PLANTAR ERYTHRODYSESTHESIA SYNDROME
3%
GASTROESOPHAGEAL REFLUX DISEASE
3%
WEIGHT LOSS
3%
PNEUMONITIS
3%
LYMPHEDEMA
3%
BREAST INFECTION
3%
ORAL PAIN
3%
FEBRILE NEUTROPENIA
3%
CREATININE INCREASED
3%
EDEMA LIMBS
3%
HYPOALBUMINEMIA
3%
INFECTIONS AND INFESTATIONS
3%
SKIN AND SUBCUTANEOUS TISSUE DISORDERS
3%
WEIGHT GAIN
3%
ALANINE AMINOTRANSFERASE INCREASED
3%
FLU LIKE SYMPTOMS
3%
SKIN ULCERATION
3%
SKIN INFECTION
3%
BREAST PAIN
1%
ALLERGIC RHINITIS
1%
VAGINAL INFECTION
1%
EDEMA FACE
1%
GENERALIZED MUSCLE WEAKNESS
1%
PRESYNCOPE
1%
DYSPHAGIA
1%
ALOPECIA
1%
WOUND DEHISCENCE
1%
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS
1%
PAPULOPUSTULAR RASH
1%
FLASHING LIGHTS
1%
PERIPHERAL MOTOR NEUROPATHY
1%
HYPERTHYROIDISM
1%
LEUKOCYTOSIS
1%
SORE THROAT
1%
MUSCLE WEAKNESS TRUNK
1%
FEVER
1%
HOARSENESS
1%
HYPERHIDROSIS
1%
NAIL INFECTION
1%
DEPRESSION
1%
DRY SKIN
1%
DERMATITIS RADIATION
1%
BONE PAIN
1%
CHOLECYSTITIS
1%
DYSESTHESIA
1%
FACIAL PAIN
1%
FALL
1%
NAIL LOSS
1%
HEMORRHOIDS
1%
LOCALIZED EDEMA
1%
AGITATION
1%
IRRITABILITY
1%
MEMORY IMPAIRMENT
1%
MUCOSAL INFECTION
1%
NECK PAIN
1%
ORAL DYSESTHESIA
1%
TELANGIECTASIA
1%
PARESTHESIA
1%
PELVIC PAIN
1%
PERSONALITY CHANGE
1%
PLEURAL EFFUSION
1%
SINUSITIS
1%
SUPERFICIAL SOFT TISSUE FIBROSIS
1%
UPPER RESPIRATORY INFECTION
1%
HYPERCALCEMIA
1%
LUNG INFECTION
1%
HYPOKALEMIA
1%
BRACHIAL PLEXOPATHY
1%
ALLERGIC REACTION
1%
FLUSHING
1%
HYPONATREMIA
1%
PERIORBITAL EDEMA
1%
PSYCHIATRIC DISORDERS
1%
SINUS PAIN
1%
EPISTAXIS
1%
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)
1%
VAGINAL INFLAMMATION
1%
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDER - OTHER, SPECIFY
1%
BLOOD BILIRUBIN INCREASED
100%
80%
60%
40%
20%
0%
Study treatment Arm
Arm A (Genomically Directed Monotherapy)
Control Arm B (Observation/Standard Therapy)
Trial Design
2Treatment groups
Experimental Treatment
Group I: Control Arm B (Observation/Standard Therapy)Experimental Treatment1 Intervention
Currently no standard therapy has proven efficacy in this patient population and thus observation alone would be considered standard of care. Additional therapy is permitted, however, if deemed appropriate by the treating physician.
Group II: Arm A (Genomically Directed Monotherapy)Experimental Treatment1 Intervention
Participants randomized to Experimental Arm A will receive an FDA approved drug at standard dose for four cycles (12-16 weeks total duration, depending on cycle length). Clinical and laboratory monitoring and dose-reductions will follow the FDA package insert guidelines.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Genomically Directed Monotherapy
2014
Completed Phase 2
~200
Find a Location
Who is running the clinical trial?
Strategic Research Initiative Grant through IUSCCUNKNOWN
Walther Cancer InstituteOTHER
24 Previous Clinical Trials
1,009 Total Patients Enrolled
2 Trials studying Breast Cancer
87 Patients Enrolled for Breast Cancer
Bryan Schneider, MDLead Sponsor
1 Previous Clinical Trials
197 Total Patients Enrolled
1 Trials studying Breast Cancer
197 Patients Enrolled for Breast Cancer
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You don't have any serious infections, as decided by your doctor.
Research Study Groups:
This trial has the following groups:- Group 1: Arm A (Genomically Directed Monotherapy)
- Group 2: Control Arm B (Observation/Standard Therapy)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there still opportunities for individuals to join this experiment?
"Clinicaltrials.gov reveals that this experiment is not actively recruiting right now, though it was initially posted on April 3rd 2014 and last updated on August 30th 2022. Nevertheless, over 4 thousand other clinical trials are looking for participants currently."
Answered by AI
Does the FDA recognize Genomically Directed Monotherapy as a viable treatment option?
"Based on the available data, Genomically Directed Monotherapy was assigned a score of 2. This evaluation is based upon Phase 2 trial results which demonstrate some safety but lack efficacy evidence."
Answered by AI
How many healthcare facilities in North America are offering this research trial?
"Participants of this medical trial are able to select from 29 sites located throughout the United States. While Gainesville, Washington and Anderson host clinical trials, there is likely a site near you that can minimize your travel requirements."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger